Biocon Ltd

Vevzuo is authorized for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone. Vevzuo is also authorized for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Evfraxy is authorized for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women this significantly reduces the risk of vertebral, non-vertebral, and hip fractures. Furthermore, Evfraxy is authorized for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, this significantly reduces the risk of vertebral fractures. Evfraxy is also authorized for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. Clinical data showed that both Denosumab biosimilars have comparable safety and efficacy to the reference product. In Europe, the European Commission (EC) recently granted marketing authorisation for Biocon Biologics Denosumab biosimilars, allowing their commercialization in all European Union (EU) member states and the European Economic Area (EEA). Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip fell 1.29% to currently trade at Rs 375.25 on the BSE. Powered by Capital Market - Live

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 372.5, up 1.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.26% on the day, quoting at 25518.4. The Sensex is at 83618.54, up 0.25%. Biocon Ltd has gained around 10.73% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 3.84% in last one month and is currently quoting at 22110.8, up 0.37% on the day. The volume in the stock stood at 26.19 lakh shares today, compared to the daily average of 65 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 374.3, up 1.3% on the day. Biocon Ltd is up 3.1% in last one year as compared to a 5% jump in NIFTY and a 9.9% jump in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live

The key equity benchmarks traded with moderate gains in morning trade. The Nifty traded above the 25,550 mark. Oil & gas shares jumped after declining in the past trading session. At 10:25 IST, the barometer index, the S&P BSE Sensex advanced 278.10 points or 0.33% to 83,687.79. The Nifty 50 index jumped 107.55 points or 0.43% to 25,561.55. In the broader market, the S&P BSE Mid-Cap index rose 0.43% and the S&P BSE Small-Cap index jumped 0.44%. The market breadth was positive. On the BSE 2,102 shares rose and 1,406 shares fell. A total of 209 shares were unchanged. New Listing: Shares of Indogulf Cropsciences were currently trading at Rs 109.50 at 10:27 IST on the BSE, representing a discount of 1.35% compared with the issue price of Rs 111. The scrip was listed at 111, matching the initial public offer (IPO) price. So far, the stock has hit a high of Rs 112.60 and a low of Rs 105.45. On the BSE, over 4.45 lakh shares of the company were traded in the counter so far. Buzzing Index: The Nifty Oil & Gas index advanced 0.70% to 11,921.55. The index declined 0.17% in the past trading session. Oil India (up 2.24%), Oil & Natural Gas Corpn (up 1.29%), GAIL (India) (up 1.18%), Gujarat State Petronet (up 1.06%), Gujarat Gas (up 0.92%), Bharat Petroleum Corporation (up 0.6%), Hindustan Petroleum Corporation (up 0.4%), Adani Total Gas (up 0.35%), Reliance Industries (up 0.31%) and Mahanagar Gas (up 0.24%) surged. Stocks in Spotlight: Biocon rose 0.42%. The company said that Biocon Biologics has received the European Commission (EC) marketing authorisation in the European Union (EU) for Vevzuo and Evfraxy biosimilars of Denosumab. Rail Vikas Nigam added 0.32%. The company said that its board has approved the appointment of Chandan Kumar Verma as chief financial officer (CFO) with effect from 2 July 2025.Powered by Capital Market - Live

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL plays a crucial role in the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By blocking RANKL, denosumab effectively inhibits the breakdown of bone, leading to increased bone mass and strength. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults. Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product. The marketing authorisation follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: 'The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including to new therapeutic areas such as bone health. In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion, and support for healthcare systems in the region.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.20% to currently trade at Rs 367.65 on the BSE. Powered by Capital Market - Live

This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor. It is prescribed for the treatment of several eye conditions. These include neovascular (wet) age-related macular degeneration (AMD). It also treats visual impairment caused by macular edema secondary to central retinal vein vein occlusion (CRVO). Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) is another indication. Furthermore, it is used for diabetic macular edema (DME). It also treats myopic choroidal neovascularization (myopic CNV). The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that YESAFILI is highly similar with no clinically meaningful differences to EYLEA in terms of quality, safety, and efficacy. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: 'The approval of YESAFILI by Health Canada'the first biosimilar to EYLEA in Canada'is a proud moment for Biocon Biologics. We are excited that in July, Canada will be the first country where we will launch YESAFILI, making it our 10th biosimilar to be commercialized worldwide.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.96% to currently trade at Rs 353.90 on the BSE. Powered by Capital Market - Live

Biocon has successfully concluded a Qualified Institutions Placement (QIP), raising Rs 4,500 crore (approximately $523 million), marking its first equity fundraise since its IPO in 2004. The company issued 13.63 crore equity shares at Rs 330 per share. The QIP opened on June 16 and closed on June 19, attracting participation from a mix of domestic and foreign institutional investors. Major names in the final orderbook included SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life, Nippon India Mutual Fund, Mirae Asset, Franklin Templeton, SBI General Insurance, Government Pension Fund Global, and BlackRock. The proceeds from the fundraise will be used for multiple strategic objectives, including purchasing optionally convertible debentures of Biocon Biologics from Goldman Sachs-managed funds, repaying certain borrowings, and meeting other financial and corporate needs. Following the issue, the combined stake of the promoter and promoter group stands at 54.45%, down from 60.64% as of March 2025. Siddharth Mittal, CEO and managing director, Biocon, said, The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.86% to settle at Rs 351.60 on Friday, 20 June 2025. Powered by Capital Market - Live

CRISIL Ratings Limited has re-affirmed the Long Term rating of Biocon at CRISIL AA+/Stable and short term rating at CRISIL A1+.Powered by Capital Market - Live

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 353.2, up 3.52% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 25209.65. The Sensex is at 82725.53, up 0.41%. Biocon Ltd has added around 7.63% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 4.53% in last one month and is currently quoting at 21948, up 0.51% on the day. The volume in the stock stood at 47.75 lakh shares today, compared to the daily average of 26.07 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 354.1, up 3.46% on the day. Biocon Ltd is up 4.22% in last one year as compared to a 8.09% gain in NIFTY and a 11.76% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live

Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge). The said approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise. The approval was received from the CDSCO under the recently formulated 101 route that enables recognition of approvals granted by established and referenced serious regulatory authorities. Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India.' Biocon is an innovation-led global biopharmaceutical company focused on improving affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the U.S. and Europe The company's consolidated net profit surged 154.2% to Rs 344.50 crore on 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The counter shed 0.45% to end at Rs 334.05 on the BSE.Powered by Capital Market - Live

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 343.8, up 1.3% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 25003.4. The Sensex is at 82230.01, down 0.12%. Biocon Ltd has added around 3.59% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 2.33% in last one month and is currently quoting at 21633.2, up 1% on the day. The volume in the stock stood at 7.5 lakh shares today, compared to the daily average of 36.71 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 344.85, up 1.2% on the day. Biocon Ltd is up 11.77% in last one year as compared to a 10.98% gain in NIFTY and a 13.77% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live